PMID- 35096864
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220201
IS  - 2296-858X (Print)
IS  - 2296-858X (Electronic)
IS  - 2296-858X (Linking)
VI  - 8
DP  - 2021
TI  - Efficacy and Safety of Ocriplasmin Use for Vitreomacular Adhesion and Its 
      Predictive Factors: A Systematic Review and Meta-Analysis.
PG  - 759311
LID - 10.3389/fmed.2021.759311 [doi]
LID - 759311
AB  - Symptomatic vitreomacular adhesion (sVMA) impedes visual acuity and quality. 
      Ocriplasmin is a recombinant protease, which may be injected into the vitreous 
      cavity to treat this condition, yet controversy remains with respect to its 
      effectiveness and safety, particularly its patient selection standard. In this 
      systematic review, the PubMed, Embase, and the Cochrane Library were searched to 
      identify studies published prior to August 2020 on the impact of ocriplasmin 
      treatment on VMA release, macular hole (MH) closure, and/or related adverse 
      events (AEs). Data were pooled using a random-effects model. Risk ratios (RRs) 
      with 95% CIs were calculated. Of 1,186 articles reviewed, 5 randomized controlled 
      trials and 50 cohort studies were ultimately included, representing 4,159 
      patients. Ocriplasmin significantly increased the rate of VMA release (RR, 3.61; 
      95% CI, 1.99-6.53; 28 days after treatment) and MH closure (RR, 3.84; 95% CI, 
      1.62-9.08; 28 days after treatment) and was associated with visual function 
      improvement. No increased risk for overall AEs was seen in ocriplasmin treatment. 
      The proportion of VMA release and MH closure in patients was 0.50 and 0.36, 
      respectively. VMA release was more likely in patients with absence of epiretinal 
      membrane (ERM). Patients with smaller MH diameter were more likely to achieve MH 
      closure. Evidence from included studies suggests that ocriplasmin is a suitable 
      and safe approach for treating sVMA. ERM and MH status are important factors when 
      considering ocriplasmin treatment.
CI  - Copyright (c) 2022 Chen, Li, You, Wang and Wang.
FAU - Chen, Xi
AU  - Chen X
AD  - Department of Ophthalmology, Beijing Friendship Hospital, Capital Medical 
      University, Beijing, China.
FAU - Li, Min
AU  - Li M
AD  - Clinical Epidemiology and Evidence-Based Medicine (EBM) Unit, National Clinical 
      Research Center for Digestive Disease, Beijing Friendship Hospital, Capital 
      Medical University, Beijing, China.
FAU - You, Ran
AU  - You R
AD  - Department of Ophthalmology, Beijing Friendship Hospital, Capital Medical 
      University, Beijing, China.
FAU - Wang, Wei
AU  - Wang W
AD  - Department of Ophthalmology, Beijing Friendship Hospital, Capital Medical 
      University, Beijing, China.
FAU - Wang, Yanling
AU  - Wang Y
AD  - Department of Ophthalmology, Beijing Friendship Hospital, Capital Medical 
      University, Beijing, China.
LA  - eng
PT  - Systematic Review
DEP - 20220113
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC8793778
OTO - NOTNLM
OT  - individual participant data analysis
OT  - macular hole (MH)
OT  - meta-analysis (as topic)
OT  - ocriplasmin
OT  - symptomatic vitreomacular adhesion/vitreomacular traction
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest. The Reviewer FL declared shared affiliation with the 
      authors to the handling Editor at time of review.
EDAT- 2022/02/01 06:00
MHDA- 2022/02/01 06:01
PMCR- 2022/01/13
CRDT- 2022/01/31 06:00
PHST- 2021/08/16 00:00 [received]
PHST- 2021/12/13 00:00 [accepted]
PHST- 2022/01/31 06:00 [entrez]
PHST- 2022/02/01 06:00 [pubmed]
PHST- 2022/02/01 06:01 [medline]
PHST- 2022/01/13 00:00 [pmc-release]
AID - 10.3389/fmed.2021.759311 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2022 Jan 13;8:759311. doi: 10.3389/fmed.2021.759311. 
      eCollection 2021.